Abstract：Objective To study Ki67, EGFR in non-triple negative and triple negative expression in breast cancer, and to explore the correlation between Ki67 and EGFR gene expression. Methods Immune histochemical method was used to detect Ki67 in specimens of 513 cases of breast cancer and the expression of EGFR, comparing both in triple negative and none triple negative breast cancer, and the correlation was analyzed by chi square and Spearman method. Results Ki67 positive expression rate in triple negative breast cancer tissues (94.32%) was significantly higher than that in triple negative breast cancer (80.47%) (P<0.05). Triple negative rate of EGFR expression in breast cancer tissue (68.18%) was significantly higher than that of non-triple negative breast cancer (11.76%) (P<0.05). Conclusions Ki67 and EGFR expression in triple negative breast cancer increases,but no correlation between both,has important significance in breast cancer prognosis judgement.
张淼,任力,胡蓉,褚晓雨,朱广卿. Ki67、EGFR在三阴性及非三阴性乳腺癌中的表达与相关性分析[J]. 武警医学, 2014, 25(12): 1256-1258.
ZHANG Miao,REN Li, HU Rong,CHU Xiaoyu,and ZHU Guangqing. Expression of Ki67,EGFR in triple negative breast cancer and correlation analysis. Med. J. Chin. Peop. Armed Poli. Forc., 2014, 25(12): 1256-1258.
Dent R,Trudeau M,Pritchard K J,et al. Triple negative breast cancer: clinical features and patterns of recurrence[J]. Clin Cancer Res,2007,13(5):4429-4434.
[2]
Morris G J, Naidu S, Topham A K, et al. Differences in breast carcinoma characteristics in newly diagnosed African- American and Caucasian patients: a single -institution compilation comparedwith the National Cancer Institute’s Surveillance,Epidemiology,and End Results database [J]. Cancer, 2007, 110(4):876-884.
[3]
Tan P H ,Bay B H,Yip G,et al.Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regu-Lation of genes related to apoptosis and cell death[J].Mod Pathol,2005,18(3):374-381.
[4]
Nalwoga H, Arnes J B, Wabinga H, et al. Expression of EGFR and ckit is associated with the basal-like phenotype in breast carcinomas of African women [J].APMIS,2008,116(6):515-525.
[6]
Reis-Filho J S, Tutt A N. Triple negative tumours: a critical review[J]. Histopathology, 2008, 52(1):108-118.
[7]
Ciulla M M, Acquistapace G, Toffetti L, et al. Ki67 cytop lasmic expression: observations in norm a l tissue from heart atr ia l appendages of healthy rats [J]. Cell Cycle, 2009,8(13):2125.
[5]
Dent R,Trudeau M,Pritchard K J,et al. Triple negative breast cancer: clinical features and patterns of recurrence[J]. Clin Cancer Res,2007,13(5):4429-4434.
[8]
Preusser M, Heinzl H, Gelpi E, et al. Ki67 index in intracran ia l ependymom a: a prom is ing h istopa tho log ical cand idate biom arke r[J]. Histopathology, 2008, 53(1):39-47.
[9]
K m D K, Kim D W, Kim S W, et al. Ki67 antigen as a predictive factor for prognosis of sinonasa lmucosal melanoma[J].Clin Exp Otorhino laryngol,2008,1(4):206-210.
[10]
Bauer K R,Brown M,Cress R D.Descriptive analysis of estrogen receptor(ER)-negative,progesterone receptor(PR)-negative, andHER2-negative invasive breast cancer, the so-called triple －negative phenotype: a population-based study from the California Cancer Registry[J].Cancer,2007,109:1721-1728.
[11]
Montemurro F, Valabrega G, Aglietta M. Lapatinib: a dual inhibitor of EGFR and HER-2 tyrosine kinase activity[J].Expert Opin Biol Ther, 2007,7(2):257-268.
[6]
Reis-Filho J S, Tutt A N. Triple negative tumours: a critical review[J]. Histopathology, 2008, 52(1):108-118.
[12]
Burness M L, Grushko T A, Olopade O I. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? [J]. Cancer J,2010,16(1):23-32.
[7]
Ciulla M M, Acquistapace G, Toffetti L, et al. Ki67 cytop lasmic expression: observations in norm a l tissue from heart atr ia l appendages of healthy rats [J]. Cell Cycle, 2009,8(13):2125.
[13]
Kim H G, Kassis J, Souto J C, et al. EGF receptor signaling in prostste morphogenesis and tumorigenesis [J]. Histol Histopathol, 1999, 14(4):1175-1182.
[14]
Pal S K, Childs B H, Pegram M. Triple negative breast cancer:unmet medical needs [J]. Breast Cancer Res Treat,2011,125(3):627-636.
[8]
Preusser M, Heinzl H, Gelpi E, et al. Ki67 index in intracran ia l ependymom a: a prom is ing h istopa tho log ical cand idate biom arke r[J]. Histopathology, 2008, 53(1):39-47.
[9]
K m D K, Kim D W, Kim S W, et al. Ki67 antigen as a predictive factor for prognosis of sinonasa lmucosal melanoma[J].Clin Exp Otorhino laryngol,2008,1(4):206-210.
[10]
Bauer K R,Brown M,Cress R D.Descriptive analysis of estrogen receptor(ER)-negative,progesterone receptor(PR)-negative, andHER2-negative invasive breast cancer, the so-called triple －negative phenotype: a population-based study from the California Cancer Registry[J].Cancer,2007,109:1721-1728.
[11]
Montemurro F, Valabrega G, Aglietta M. Lapatinib: a dual inhibitor of EGFR and HER-2 tyrosine kinase activity[J].Expert Opin Biol Ther, 2007,7(2):257-268.
[12]
Burness M L, Grushko T A, Olopade O I. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? [J]. Cancer J,2010,16(1):23-32.
[13]
Kim H G, Kassis J, Souto J C, et al. EGF receptor signaling in prostste morphogenesis and tumorigenesis [J]. Histol Histopathol, 1999, 14(4):1175-1182.
[14]
Pal S K, Childs B H, Pegram M. Triple negative breast cancer:unmet medical needs [J]. Breast Cancer Res Treat,2011,125(3):627-636.
2014, Vol. 25 
